IMMIX BIOPHARMA INC. - COMMON STOCK
2.3500
03-5月-24 15:59:58
15 分の遅延
株式
+0.0400
+1.73%
本日の幅
2.3100 - 2.5100
ISIN
N/A
ソース
NASDAQ
-
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
29 4 2024 09:39:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma on Track to Dose NXC-201 Patients in United States
18 4 2024 09:32:00 提供 Nasdaq GlobeNewswire
-
20 3 2024 09:46:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
05 3 2024 09:35:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma 12 Month Review Progress Update
21 2 2024 09:31:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
08 2 2024 16:45:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
07 2 2024 09:37:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
05 2 2024 22:30:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma Announces Proposed Public Offering of Common Stock
05 2 2024 15:20:11 提供 Nasdaq GlobeNewswire
-
24 1 2024 08:35:00 提供 Nasdaq GlobeNewswire
-
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
30 11 2023 09:46:00 提供 Nasdaq GlobeNewswire
-
22 11 2023 09:19:00 提供 Nasdaq GlobeNewswire
-
21 11 2023 09:46:00 提供 Nasdaq GlobeNewswire
-
21 11 2023 09:46:00 提供 Nasdaq GlobeNewswire
-
06 11 2023 09:12:00 提供 Nasdaq GlobeNewswire
-
06 11 2023 08:40:00 提供 Nasdaq GlobeNewswire
- <<
- <
- 1
- >